Global Plasma Fractionation Market Is Expected To Reach USD 46 Billion By 2027 At A CAGR Of 6.89 percent.
Maximize Market Research has published a report on the Global Plasma Fractionation Market that provides a detailed analysis for the forecast period of 2022 to 2029.
Global Plasma Fractionation Market Scope:
The report provides comprehensive market insights for industry stakeholders, including an explanation of complicated market data in simple language, the industry’s history and present situation, as well as expected market size and trends. The research investigates all industry categories, with an emphasis on key companies such as market leaders, followers, and new entrants. The paper includes a full PESTLE analysis for each country. A thorough picture of the competitive landscape of major competitors in the Global Plasma Fractionation market by goods and services, revenue, financial situation, portfolio, growth plans, and geographical presence makes the study an investor’s guide.
Request Free Sample:@https://www.maximizemarketresearch.com/request-sample/6677
Global Plasma Fractionation Market Overview:
Fractionation is a technique used to separate specific amounts of a mixture. Additionally, blood’s fluid component, plasma, is fractionated to produce several plasma derivatives including albumin and immunoglobulins. These plasma-derived compounds are used to treat a variety of blood plasma-related diseases and have therapeutic effects. Consider the plasma derivative coagulation factor VIII, which is used to prevent and treat hemophilia. Additionally, it is used to prevent excessive blood loss during surgery. Immunoglobulins are used in a similar way to treat both primary and secondary immunological deficiencies.
Global Plasma Fractionation Market Dynamics:
Treatment of hepatic and pulmonary conditions, including emphysema, has seen a considerable increase in the use of protease inhibitors such as alpha-1-antitrypsin (such as hepatic inflammation, fibrosis, and cirrhosis). Undiagnosed and persistent, alpha-1-antitrypsin deficiency (AATD) is a hereditary metabolic condition. In the US, it causes 2 percent to 3 percent of all instances of emphysema. Alpha-1-antitrypsin deficiency causes pan lobular emphysema to develop early in smokers and non-smokers, and aberrant alpha-1-antitrypsin buildup in the liver causes illnesses. AATD happens everywhere, but the prevalence varies by region. The NIH estimates that 1 in 1,500–3,500 people in European nations have AATD. On the other side, the APAC area has a low prevalence of AATD. Alpha-1-antitrypsin deficiency causes the creation of scar tissue in the liver, which causes about 10 percent of babies to experience liver disorders and 15 percent of adults to experience cirrhosis, or liver damage.
Combined with chronic bronchitis, emphysema is referred to as chronic obstructive pulmonary disease (COPD). According to the Forum of International Respiratory Societies’ Global Impact of Respiratory Disease study, COPD affects around 65 million people and accounts for 3 million deaths annually. This makes it the third greatest cause of mortality globally. Moreover, a genetic lack of the alpha-1-antitrypsin gene accounts for around 2 percent of instances of emphysema. Also, with an estimated 3.9 million fatalities, or 7 percent of all deaths, chronic respiratory disorders offer a serious public health issue.
The number of persons receiving treatments for AATD and emphysema is anticipated to rise as a result of the increasing frequency of these diseases and advancements in diagnostic methods like CT scanning. In turn, this increases demand for protease inhibitors like alpha-1-antitrypsin and supports the market growth for plasma fractionation as a whole.
The World Health Organization and Clinical and Diagnostic Centers in the US, China, and many other nations developed strict laboratory biosafety protocols for SARS-CoV-2. For laboratory employees handling samples from SARS-CoV-2 cases that were suspected or confirmed, biosafety Level 3 protection was advised. Biosafety protection procedures were also to be followed in order to reduce the danger of virus spread.
To lower the potential of aerosol transmission, the waiting period after centrifugation was extended, and further steps were added to laboratory protocols, such as spraying with 75 percent ethanol to disinfect and performing manual processes in biological safety cabinets. A shortage of plasma products during the pandemic resulted from the availability of plasma fractionation products being significantly impacted by such stringent lab procedures and heightened safety measures.
One of the main applications for plasma fractionation products is hemophilia or hematological disorders. Hemophilia is a genetic bleeding illness marked by poor blood coagulation as a result of defects in coagulation factor VIII production or action. One in 5,000 men has hemophilia A. Each year, 400 infants are born with hemophilia A. The World Federation of Hemophilia reports that there are now 210,454 hemophilia patients, up from 167,110.
Only 30 percent of people acquire a hemophilia diagnosis, and only 25 percent of them undergo treatment. The other patients are still undiagnosed, and over 75 percent of them receive subpar or no care at all. But over the past ten years, the rate of hemophilia diagnosis and treatment has increased.
Global Plasma Fractionation Market Regional Insights:
The plasma fractionation market was dominated by North America, with smaller shares held by Europe and the Asia-Pacific region. Due to the growing usage of preventative treatments among diagnosed patients as well as the increasing use of immunoglobulins in neurological and autoimmune illnesses, North America now accounts for a sizable portion of the global market. The large number of patients with hemophilia who have registered further fuels the expansion of this sector. The market for plasma fractionation in North America will be driven by the increasing adoption of coagulation factors due to the rising number of hemophilic patients.
Global Plasma Fractionation Market Segmentation:
By Type:
- Immunoglobulins
- Coagulation Factor Concentrates
- Albumin
- Protease Inhibitors
- Other
By Application:
- Immunology
- Hematology
- Neurology
- Critical Care
- Hemato-Oncology
- Rheumatology
- Others
By Processing technology:
- Ion-Exchange Chromatography
- Affinity Chromatography
- Cryopreservation
- Ultrafiltration
- Microfiltration
By End-User:
- Hospitals & Clinics
- Clinical Research Laboratories
- Academic Institutions
- Others
Global Plasma Fractionation Market Key Competitors:
- Bio Products Laboratory
- Biotest AG
- China Biologic Products Holdings Inc.
- CSL Limited
- Green Cross Corporation
- Grifols
- Japan Blood Products Organization
- Kedrion
- LFB group
- Octapharma AG
- Sanquin Blood Supply Foundation
- Takeda Pharmaceutical Company Limited.
- Baxter
- Green Cross Corporation
- Shanghai RAAS
- Bharat Serums and Vaccines Limited
- Merck KGaA
- ADMA Biologics
- Boccard
- Intas Pharmaceuticals Ltd.
To Get A Copy Of The Sample of the Global Plasma Fractionation Market, Click Here:@https://www.maximizemarketresearch.com/market-report/global-plasma-fractionation-market/6677/
About Maximize Market Research:
Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.
Contact Maximize Market Research:
3rd Floor, Navale IT Park, Phase 2
Pune Banglore Highway, Narhe,
Pune, Maharashtra 411041, India
sales@maximizemarketresearch.com
